An Observational Study of Long-term Peritoneal Dialysis Patients Who Eventually Develop Ultrafiltration Failure (LUFF)

NCT05721703 · tracked via the Priya Life Science China tracker

Sponsor

Chinese PLA General Hospital

Phase

Observational

Started

2021-05-21

Last updated

2023-02-14

Condition(s) studied

Ultrafiltration Failure

Study summary

At present, there are few researches on peritoneal dialysis, especially on ultrafiltration failure of peritoneal dialysis. To explore the regularity and mechanism of peritoneal ultrafiltration failure,investigators followed up the comprehensive data of participants from the insertion to the removal of the peritoneal dialysis catheter, and collected the peritoneal tissue for morphological and single-cell analysis when the participants inserting or removing their catheters. If the catheter is still in use when this study stop collecting data, the peritoneal dialysis effluent will substitute for peritoneal tissue to the morphological and single-cell analysis. Clinical data and single-cell sequence data were processed using statistical analyses to identify factors affecting ultrafiltration failure.

Eligibility

Sex

ALL

Min age

18 Years

Max age

70 Years

Healthy volunteers

Inclusion Criteria: 1. Clinically diagnosed as chronic renal insufficiency (CKD 5) 2. Patients who met the first dialysis guidelines for peritoneal dialysis without catheter, or patients with peritoneal dialysis regularly, or ultrafiltration failure was diagnosed and patients on peritoneal dialysis were to be existed. 3. Written informed consent signed by the patient or the authorized client has been obtained. Exclusion Criteria: 1. Acute renal failure. 2. Pregnant or lactating women. 3. Active infection duration. 4. One of infectious serum markers of HIV, syphilis, hepatitis B and hepatitis C is positive. 5. Any other conditions that the investigator considers impossible to join this trial.

Primary outcome measure(s)

Technical survival rate — 8 year
Technical survival of peritoneal dialysis

Trial sites (1)

Facility	City	Region	Status
Chinese PLA General Hospital	Beijing	Beijing Municipality

More Chinese PLA General Hospital trials in China

Management of Age-Related Auditory Decline and Early Warning of Its Co-occurring Dementia Starting soon

Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. Recruiting

Chinese, Overweight or Obesity, Real-World Registry Study Starting soon

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas Recruiting

GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05721703 on ClinicalTrials.gov ↗ ← All trials in China